Gene Therapy: Key Payer Considerations

Est. Reading Time: 3 min

Gene therapy is rapidly reshaping what is clinically possible in healthcare. Once considered experimental, these treatments are now delivering one-time interventions that can dramatically alter or even cure rare genetic diseases. But with price tags that often exceed $1 million per patient, gene therapies also introduce a new level of financial and operational complexity for employer-sponsored health plans.

Given the burgeoning pipeline of new gene therapies, it is essential that plan sponsors and their broker partners understand the key clinical, operational, and financial implications of these medical innovations to optimize access and value for both members and the organization.

What is gene therapy and how does it work?

The FDA defines gene therapy as “a technique that modifies a person’s genes to treat or cure disease.” It works by a few potential mechanisms, including:

Replacing a disease-causing gene with a healthy copy of the gene
Inactivating a disease-causing gene that is not functioning properly
Introducing a new or modified gene into the body to help treat a disease

Viral vector therapies are one example. Because of the natural ability of viruses to deliver genetic materials to cells, it’s possible to modify a virus to eliminate its ability to cause infectious disease and instead function as a vector (a delivery mechanism) that carries therapeutic genetic material into human cells.

Gene therapy is a life-changing treatment

Where previously a patient may have had few or no options to manage or cure their rare genetic disease, extensive development of new gene therapies could provide symptom relief and pathways to cure for millions of people.

Since 2017, the FDA has approved ten ultra-high-cost gene therapies. Below are the ten gene therapy treatments that are FDA approved one-time therapies priced over $1 million that represent the current landscape of gene editing and gene-adding treatments available, as of 2026.

Additionally, there are about 6 new gene therapy treatments in the pipeline, expected to launch in 2026. As gene therapies continue to be developed to address a wider variety of conditions, these treatments will not only empower healthcare providers to offer specialized care for patients, but also increase the usage of high-cost specialty drugs. In turn, plan sponsors and their broker partners will need to determine an effective strategy to provide patient access while managing costs.

Assess your benefit program’s readiness for gene therapy coverage

Gene therapy is reshaping the cost structure and risk exposure of employer health plans. Although life-changing for patients, these therapies introduce significant financial and operational complexity, requiring proactive forecasting and clear visibility into existing plan protections.

Evaluate how gene therapy is currently covered on the plan – Brokers and plan sponsors should begin with a benefit-level audit to understand precisely where and how gene therapies are covered to determine cost exposure, reimbursement pathways, and the utilization-management rules that apply. It’s important to ensure utilization management is stringent and includes documentation requirements for diagnosis as well as site-of-care restrictions.
Review contracting and network structure for gaps – Evaluate if gene therapy is covered only through centers of excellence or more broadly accessible. A narrow network of specialists can support more reasonable reimbursement rates and help to ensure any potential coverage is appropriate. Assess PBM contracting terms for gene therapy, including reimbursement rates and discounts, and check for any clauses that could shift liability back to the employer in the absence of specialized negotiation. This evaluation is critical since network design determines unit price variation, which can be hundreds of thousands of dollars in the case of gene therapy.
Request predictive modeling from the health plan – Health plans increasingly have the ability to run predictive models based on known diagnostic and clinical indictors within populations. Brokers and plan sponsors should request modeling to identify members already diagnosed with conditions that have approved or near-term gene therapies. This can be used for proactive forecasting of potential future utilization.
Assess stop-loss coverage and supplemental risk protection options – Since gene therapy claims routinely exceed $1 million, stop-loss protection must be evaluated with heightened scrutiny. Review specific deductibles to ensure they align with the current cost profile of gene therapies. Confirm whether stop-loss carrier covers gene therapy without limitations, exclusions, or stop-loss caps. Evaluate gene therapy-specific riders, captive arrangements, or supplemental reinsurance for added protection. Also, explore options like outcome-based or installment-based payment programs offered by payers or third-party vendors.

Gene therapy introduces new opportunities for improved patient outcomes alongside significant financial complexity for employer health plans. By closely evaluating benefit design, network strategy, and risk protections, brokers and plan sponsors can navigate the expanding gene therapy landscape with a thoughtful, proactive approach.